The NAD Dependent Protein Deacetylase Sirtuin 6 pipeline drugs market research report outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the NAD Dependent Protein Deacetylase Sirtuin 6 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Oncology, Hormonal Disorders, and Undisclosed which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Ulcerative Colitis, Oncology, Pancreatic Ductal Adenocarcinoma, Werner Syndrome, and Unspecified. It also reviews key players involved in NAD Dependent Protein Deacetylase Sirtuin 6 targeted therapeutics development with respective active and dormant or discontinued products.
The NAD Dependent Protein Deacetylase Sirtuin 6 pipeline targets constitutes close to nine molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 1, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
NAD Dependent Protein Deacetylase Sirtuin 6 overview
NAD-Dependent Protein Deacetylase Sirtuin 6 (SIRT6) is a member of the sirtuin family of proteins, which are class III histone deacetylases involved in various cellular processes, including metabolism, stress response, and longevity. SIRT6 is primarily localized in the nucleus and functions as a deacetylase, removing acetyl groups from histones and non-histone proteins. By deacetylating histones, SIRT6 modulates gene expression, particularly those genes associated with cellular senescence, DNA repair, and metabolism. SIRT6 has been linked to the maintenance of genomic stability and the prevention of DNA damage. SIRT6 also plays a crucial role in metabolic homeostasis. It has been implicated in the regulation of glucose metabolism, insulin sensitivity, and lipid metabolism. Moreover, SIRT6 is involved in the cellular response to stress. Dysregulation of SIRT6 has been implicated in several age-related diseases, including metabolic disorders, neurodegenerative diseases, and cancer.
For a complete picture of NAD Dependent Protein Deacetylase Sirtuin 6’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
